



Traxam

Preparation Date 23-Apr-2007

Revision Date 29-Jan-2008

Revision Number 1

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name Traxam
Common Name Not available
Chemical Name Not applicable
Synonyms Felbinac, CL-83544, Felbinaakki, Felbinaco, Felbinacum, Felbinak, LJC-10141
Product Use Pharmaceutical product
Classification Analgesic Anti-Inflammatory Drug and Antipyretic
Supplier Wyeth
P.O. Box 8299
Philadelphia, PA 19101 USA.
Telephone: 1-610-688-4400

Emergency Telephone Number Chemtrec USA, Puerto Rico, Canada 1-800-424-9300
Chemtrec International 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical Gel or Foam **Physical State** Solid **Odor** Not available

Potential Physical Hazards Powders and solids are presumed to be combustible.

Potential Health Effects

Eyes
Skin

May cause eye irritation.

The most common effects may include erythema, dermatitis, and pruritus including bullous dermatoses such as epidermal necrolysis and erythema multiforme; photosensitivity, anaphylaxis, and bronchospasm or wheezing; gastrointestinal disturbances.

Inhalation
Ingestion

Not available

Harmful if swallowed. Ingestion may cause gastrointestinal tract irritation, nausea, vomiting, diarrhea and respiratory system effects.

May cause harm to the unborn child. May be excreted in breast milk.

Please see Patient Package Insert for further information.

Therapeutic Target Organ(s)

Skin.

Not listed by OSHA, NTP or IARC.

Potential Environmental Effects

There is no known ecological information for this product.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	Composition
Felbinac	5728-52-9	3 - 3.17%
Inactive Ingredients	Not applicable	Remainder

4. FIRST AID MEASURES

Eye Contact	In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.
Skin Contact	Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
Inhalation	Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.
Ingestion	If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties	Presumed to be a combustible particulate solid.
Extinguishing Media	
Suitable Extinguishing Media	Use water spray, foam, dry chemical or carbon dioxide.
Unsuitable Extinguishing Media	Do NOT use water jet.
Fire Fighting	Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.
Hazardous Combustion Products	Carbon oxides, nitrogen oxides.
Protective Equipment and Precautions for Firefighters	In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Refer to protective measures listed in Sections 7 and 8.
Environmental Precautions	Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.
Methods for Containment	Not available
Methods for Cleaning up	Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling	For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.
Storage	No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name Felbinac	Exposure Guideline 60 mcg/m ³
Engineering Controls	Apply technical measures to comply with the occupational exposure guideline. Local exhaust ventilation is needed for limited open handling or where aerosols may be generated.
Personal Protective Equipment	
Eye/face Protection	Provide eye protection based on risk assessment.
Skin Protection	Wear nitrile or latex gloves. Wear protective garment.
Respiratory Protection	Base respirator selection on a risk assessment.
General Hygiene Considerations	When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.
Other	Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	Pharmaceutical Gel or Foam	Physical State	Solid
Color	Not available	Odor	Not available
Odor Threshold	Not available		
pH	Not applicable		
Specific Gravity	Not applicable	Water Solubility	Practically insoluble in water
Solubility	Not applicable	Evaporation Rate	Not applicable
Partition Coefficient (n-octanol/water)	Not available	Vapor Pressure	Not applicable
Boiling Point	Not applicable	Autoignition Temperature	Not applicable
Flash Point	Not available	Method	None
Melting Point	Not available		
Flammability Limits in Air	Upper Not applicable	Lower Not applicable	
Explosion Limits	Upper Not applicable	Lower Not applicable	

10. STABILITY AND REACTIVITY

Chemical Stability	Stable at room temperature.
Conditions to Avoid	No data available
Materials to Avoid	No materials to be especially mentioned.
Hazardous Decomposition Products	None under normal use.
Possibility of Hazardous Reactions	None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Felbinac

LD50 Oral	164 mg/kg rats, 495 mg/kg rats (IP); 148 mg/kg rats (SC)
Acute Dermal Irritation	No data available
Primary Eye Irritation	No data available
Sensitization	No data available

Multiple Dose Toxicity

Felbinac

No Toxicologic Effect Dose/Species/Study Length:	In a 30-day study in rats, subcutaneous doses of 900 mg/kg/day. caused toxic effects in the liver and in the blood. In a 26-week Rat study, subcutaneous doses of 3640 mg/kg/day caused toxic effects in the liver, kidneys, blood and spleen.
---	--

Maximum Tolerated Dose (MTD), Oral

Felbinac

Carcinogenicity	No data available
Genetic Toxicity	No data available
Reproductive Toxicity	Reproduction studies were performed in lactating females by subcutaneous injection. Maternal effects observed included weight changes, decreased food consumption, digestive system effects and effects on the duration of gestation.
Developmental Toxicity	Developmental studies in female rats and rabbits were carried out at subcutaneous doses after conception. maternal weight changes, decreased food consumption, vaginal and uterine bleeding, fetal loss and developmental abnormalities were observed

Felbinac

Target Organ(s) of Toxicity	No data available
------------------------------------	-------------------

12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information Not available

Ecotoxicity Not available

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)	Not regulated
Canadian Transport of Dangerous Goods (TDG)	Not regulated
International Civil Aviation Organization (ICAO)	Not regulated
International Air Transport Association (IATA)	Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO)	Not regulated
Transport of Dangerous Goods by Rail (RID)	Not regulated
Transport of Dangerous Goods by Road (ADR)	Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN)	Not regulated

15. REGULATORY INFORMATION

USA

Federal Regulations

OSHA Regulatory Status

This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazardous Categorization

Acute Health Hazard	No
Chronic Health Hazard	No
Fire Hazard	No
Sudden Release of Pressure Hazard	No
Reactive Hazard	No

This product does not contain any HAPs..

State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

Canada

Not classified

WHMIS Hazard Class

Non-controlled

European Union

In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

16. OTHER INFORMATION

Prepared By	Wyeth Department of Environment, Health & Safety
Format	This MSDS was prepared in accordance with ANSI Z400.1-2004.
List of References	See Patient Package Insert for more information.
Revision Summary	Administrative

Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS